Literature DB >> 15831716

Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Kartik Chandran1, Nancy J Sullivan, Ute Felbor, Sean P Whelan, James M Cunningham.   

Abstract

Ebola virus (EboV) causes rapidly fatal hemorrhagic fever in humans and there is currently no effective treatment. We found that the infection of African green monkey kidney (Vero) cells by vesicular stomatitis viruses bearing the EboV glycoprotein (GP) requires the activity of endosomal cysteine proteases. Using selective protease inhibitors and protease-deficient cell lines, we identified an essential role for cathepsin B (CatB) and an accessory role for cathepsin L (CatL) in EboV GP-dependent entry. Biochemical studies demonstrate that CatB and CatL mediate entry by carrying out proteolysis of the EboV GP subunit GP1 and support a multistep mechanism that explains the relative contributions of these enzymes to infection. CatB and CatB/CatL inhibitors diminish the multiplication of infectious EboV-Zaire in cultured cells and may merit investigation as anti-EboV drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831716      PMCID: PMC4797943          DOI: 10.1126/science.1110656

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  24 in total

1.  Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection.

Authors:  Graham Simmons; Andrew J Rennekamp; Ning Chai; Luk H Vandenberghe; James L Riley; Paul Bates
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 2.  Animal cell invasion by a large nonenveloped virus: reovirus delivers the goods.

Authors:  Kartik Chandran; Max L Nibert
Journal:  Trends Microbiol       Date:  2003-08       Impact factor: 17.079

Review 3.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

4.  Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.

Authors:  W Weissenhorn; A Carfí; K H Lee; J J Skehel; D C Wiley
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

5.  Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation.

Authors:  J Deussing; W Roth; P Saftig; C Peters; H L Ploegh; J A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

6.  Covalent modifications of the ebola virus glycoprotein.

Authors:  Scott A Jeffers; David Avram Sanders; Anthony Sanchez
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro.

Authors:  M Murata; S Miyashita; C Yokoo; M Tamai; K Hanada; K Hatayama; T Towatari; T Nikawa; N Katunuma
Journal:  FEBS Lett       Date:  1991-03-25       Impact factor: 4.124

8.  Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution.

Authors:  V N Malashkevich; B J Schneider; M L McNally; M A Milhollen; J X Pang; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

9.  Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.

Authors:  H Ito; S Watanabe; A Sanchez; M A Whitt; Y Kawaoka
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

10.  The influenza hemagglutinin precursor as an acid-sensitive probe of the biosynthetic pathway.

Authors:  F Boulay; R W Doms; I Wilson; A Helenius
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

View more
  478 in total

1.  Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.

Authors:  Shutoku Matsuyama; Noriyo Nagata; Kazuya Shirato; Miyuki Kawase; Makoto Takeda; Fumihiro Taguchi
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Authors:  Gopi S Mohan; Ling Ye; Wenfang Li; Ana Monteiro; Xiaoqian Lin; Bishu Sapkota; Brian P Pollack; Richard W Compans; Chinglai Yang
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

4.  Genetic inactivation of COPI coatomer separately inhibits vesicular stomatitis virus entry and gene expression.

Authors:  David K Cureton; Rebeca Burdeinick-Kerr; Sean P J Whelan
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

5.  Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

Authors:  John Misasi; Kartik Chandran; Jin-Yi Yang; Bryden Considine; Claire Marie Filone; Marceline Côté; Nancy Sullivan; Giulia Fabozzi; Lisa Hensley; James Cunningham
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

6.  Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.

Authors:  Daniel Olal; Ana I Kuehne; Shridhar Bale; Peter Halfmann; Takao Hashiguchi; Marnie L Fusco; Jeffrey E Lee; Liam B King; Yoshihiro Kawaoka; John M Dye; Erica Ollmann Saphire
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

7.  Modeling the step of endosomal escape during cell infection by a nonenveloped virus.

Authors:  Thibault Lagache; Olivier Danos; David Holcman
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

8.  Viral infection: Moving through complex and dynamic cell-membrane structures.

Authors:  Jonathan Barroso-González; Laura García-Expósito; Julià Blanco; Agustín Valenzuela-Fernández; Isabel Puigdomènech; Laura de Armas-Rillo; José-David Machado
Journal:  Commun Integr Biol       Date:  2011-07-01

9.  Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein.

Authors:  S M de Boer; J Kortekaas; L Spel; P J M Rottier; R J M Moormann; B J Bosch
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines.

Authors:  Heike Hofmann; Xingxing Li; Xiaoai Zhang; Wei Liu; Annika Kühl; Franziska Kaup; Samantha S Soldan; Francisco González-Scarano; Friedemann Weber; Yuxian He; Stefan Pöhlmann
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.